Truist raises Edwards Lifesciences stock price target on TAVR growth By Investing.com

Truist Securities raised its Edwards Lifesciences price target to $90 from $89 while maintaining a Hold rating, citing continued double-digit TAVR momentum and upside that lifted fiscal 2026 revenue and earnings guidance. The firm expects incremental U.S. share gains at Medtronic’s expense and sees catalysts for TAVR and TMTT in the second half of 2026-2027. The article also notes the company beat Q1 estimates, with revenue of $1.65 billion versus $1.60 billion consensus and EPS of $0.78 versus $0.73.

Analysis

EW’s setup is increasingly a classic “good business, expensive stock” debate rather than a fundamental knock. The market is paying for durability in a category where share gains can compound for years, but the incremental upside from here likely depends on whether the next leg of growth comes from a genuine new product cycle rather than just continued execution in the core franchise. That makes the key variable not 2026 estimates, but whether the company can re-accelerate into a second derivative earnings stream before the multiple starts to compress.

The competitive read-through is more important for MDT than for EW. If Edwards keeps taking share in structural heart, the pain is not just lost revenue but weaker pricing power and a tougher capital allocation story for Medtronic in a segment where investor patience is already low; that can pressure the broader med-tech complex by reinforcing a “winner takes share” narrative. Second-order, suppliers tied to cath lab utilization and procedural growth should see steadier demand, while hospital buyers may have less leverage if Edwards’ installed base keeps expanding.

The real risk is timing: the stock can look optically cheap on growth metrics for months if the market believes the next catalyst is 12-18 months out, but that same setup can unwind quickly if TAVR growth decelerates even modestly or if the next innovation step is pushed out. The premium multiple leaves little room for a miss, especially if reimbursement, procedure volumes, or competitive launches create any evidence of plateauing in late 2026. In other words, the upside case is path-dependent, but the downside can be immediate if the growth curve flattens before the TMTT narrative inflects.

Consensus seems comfortable underwriting “steady compounder” status, but the more interesting debate is whether EW deserves a higher duration multiple at all without proof that TMTT becomes a material earnings contributor. If that catalyst slips, the market may stop paying for optionality and re-rate the name toward a lower-teens growth multiple on a forward basis. The stock is not obviously broken, but the bar for another step-up in valuation is probably higher than the current narrative implies.

Key Decisions for Investors

• Maintain a tactical long EW bias only on pullbacks, with a 3-6 month horizon; use the stock as a quality-growth compounder, but size modestly because the multiple already discounts a strong execution path.
• Avoid initiating fresh long EW after sharp post-earnings strength unless TMTT can show a clearer inflection; risk/reward is asymmetric to the downside if growth merely stays good instead of accelerating.
• Consider a pair trade: long EW / short MDT for 6-12 months to express continued share capture in structural heart; the trade works if Edwards keeps outperforming while Medtronic’s segment growth remains pressured.
• For options traders, prefer selling put spreads in EW over buying upside calls; the premium valuation makes outright upside dependent on a catalyst that may not arrive until 2H 2026, while near-term downside is cushioned by the quality narrative.
• Set a catalyst watch on future TMTT quarters: if adoption inflects and starts contributing visibly to growth mix, re-underwrite for a higher multiple; if not, take profits on EW longs before the market begins to price a maturity discount.